| Subject: | FDA Releases Information on Revised Prescribing Information for Haloperidol |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 18 Sep 2007 - 09:00 am |
| Audience: Neuropsychiatric and cardiovascular specialists, other healthcare professionalsThe FDA and Johnson & Johnson are informing healthcare professionals that the WARNINGS section of the prescribing information for haloperidol (marketed as Haldol, Haldol decanoate, and Haldol lactate) has been revised to include a new Cardiovascular subsection regarding cases of sudden death, QT prolongation and Torsades de Pointes(TdP) in patients treated with haloperidol, especially when given... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
External Links:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. Other vendors have components of legislated requirements available online or on CD-ROM. However there is no other product that marries regulatory agency mandates with implementation tools, making the latest compliance information immediately available online. No other product provides an interpretative analysis, followed by a practical application tool, therefore providing users with an immediate solution to compliance problems. StayAlert! includes operational components for healthcare organizations, allowing complete facility compliance with mandated requirements, online. |
|
